Dayaolingzhiols A−E, AchE inhibitory meroterpenoids from Ganoderma lucidum

The Biological Activity of Ganoderma lucidum on Neurodegenerative Diseases: The Interplay between Different Active Compounds and the Pathological Hallmarks

Neurodegenerative diseases represent a cluster of conditions characterized by the progressive degeneration of the structure and function of the nervous system. Despite significant advancements in understanding these diseases, therapeutic options remain limited. The medicinal mushroom Ganoderma lucidum has been recognized for its comprehensive array of bioactive compounds with anti-inflammatory and antioxidative effects, which possess potential neuroprotective properties. This literature review collates and examines the existing research on the bioactivity of active compounds and extracts from Ganoderma lucidum in modulating the pathological hallmarks of neurodegenerative diseases. The structural information and preparation processes of specific components, such as individual ganoderic acids and unique fractions of polysaccharides, are presented in detail to facilitate structure-activity relationship research and scale up the investigation of in vivo pharmacology. The mechanisms of these components against neurodegenerative diseases are discussed on multiple levels and elaborately categorized in different patterns. It is clearly presented from the patterns that most polysaccharides of Ganoderma lucidum possess neurotrophic effects, while ganoderic acids preferentially target specific pathogenic proteins as well as regulating autophagy. Further clinical trials are necessary to assess the translational potential of these components in the development of novel multi-target drugs for neurodegenerative diseases.

Insights into Ganoderma fungi meroterpenoids opening a new era of racemic natural products in mushrooms

Ganoderma meroterpenoids (GMs) containing 688 structures to date were discovered to have multiple remarkable biological activities. 65.6% of meroterpenoids featuring stereogenic centers from Ganoderma species are racemates. Further, GMs from different Ganoderma species seem to have their own characteristics. In this review, a comprehensive summarization of GMs since 2000 is presented, including GM structures, structure corrections, biological activities, physicochemical properties, total synthesis, and proposed biosynthetic pathways. Additionally, we especially discuss the racemic nature, species-related structural distribution, and structure-activity relationship of GMs, which will provide a likely in-house database and shed light on future studies on GMs.

Therapeutic potential of the medicinal mushroom Ganoderma lucidum against Alzheimer's disease

Alzheimer's disease (AD) is a high-incidence neurodegenerative disorder, characterized by cognitive impairment, memory loss, and psychiatric abnormalities. Ganoderma lucidum is a famous medicinal fungus with a long history of dietary intake, containing various bioactive components, and have been documented to exhibit antioxidant, anti-inflammatory, anti-tumor, anti-aging, and immunomodulatory effects, among others. Recent studies have shown that G. lucidum and its components have promising therapeutic potential against AD from various aspects, which can delay the progression of AD, improve cognitive function and quality of life. The underlying mechanisms mainly include inhibiting tau hyperphosphorylation, inhibiting Aβ formation, affecting activated microglia, regulating NF-κB/MAPK signalling pathway, inhibiting neuronal apoptosis, modulating immune system, and inhibiting acetylcholinesterase, etc. This paper systematically reviewed the relevant studies on the therapeutic potential of G. lucidum and its active components for treatment of AD, key points related with the mechanism studies and clinical trials have been discussed, and further perspectives have been proposed. Totally, as a natural medicinal mushroom, G. lucidum has the potential to be developed as effective adjuvant for AD treatment owing to its therapeutic efficacy against multiple pathogenesis of AD. Further mechanical investigation and clinical trials can help unlock the complete potential of G. lucidum as a therapeutic option for AD.

Neuroprotective, neurogenic, and anticholinergic evidence of Ganoderma lucidum cognitive effects: Crucial knowledge is still lacking

Ganoderma lucidum is a mushroom that has been widely used for centuries in Asian countries for its antiaging properties. It is popularly known as "Ling Zhi," "Reishi," and "Youngzhi," and because of its benefits, it is known as the "immortality mushroom." Pharmacological assays have revealed that G. lucidum ameliorates cognitive impairments through inhibition of β-amyloid and neurofibrillary tangle formation, antioxidant effect, reduction of inflammatory cytokine release and apoptosis, genic expression modulation, among other activities. Chemical investigations on G. lucidum have revealed the presence of metabolites such as triterpenes, which are the most explored in this field, as well as flavonoids, steroids, benzofurans, and alkaloids; in the literature, these have also been reported to have mnemonic activity. These properties of the mushroom make it a potential source of new drugs to prevent or reverse memory disorders, as actual medications are able to only alleviate some symptoms but are unable to stop the progress of cognitive impairments, with no impact on social, familiar, and personal relevance. In this review, we discuss the cognitive findings of G. lucidum reported in the literature, converging the proposed mechanisms through the several pathways that underlie memory and cognition processes. In addition, we highlight the gaps that deserve particular attention to support future studies.

Structural diversity, hypothetical biosynthesis, chemical synthesis, and biological activity of Ganoderma meroterpenoids

Covering: 2018 to 2022Meroterpenoids found in fungal species of the genus Ganoderma and known as Ganoderma meroterpenoids (GMs) are substances composed of a 1,2,4-trisubstituted benzene and a polyunsaturated side chain. These substances have attracted the attention of chemists and pharmacologists due to their diverse structures and significant bioactivity. In this review, we present the structures and possible biosynthesis of representative GMs newly found from 2018 to 2022, as well as chemical synthesis and biological activity of some interesting GMs. We propose for the first time a plausible biosynthetic pathway for GMs, which will certainly motivate further research on the biosynthetic pathway in Ganoderma species, as well as on chemical synthesis of GMs as important bioactive compounds for the purpose of drug development.

Natural sesquiterpene quinone/quinols: chemistry, biological activity, and synthesis

Covering: 2010 to 2021Sesquiterpene quinone/quinols (SQs) are characterized by a C15-sesquiterpenoid unit incorporating a C6-benzoquinone/quinol moiety. Numerous unprecedented carbon skeletons have been constructed with various connection patterns between the two parts. The potent anti-cancer, anti-inflammatory, anti-microbial, anti-viral, and fibrinolytic activities of SQs are associated with their diverse structures. The representative avarol has even entered the stage of clinical phase II research as an anti-HIV agent, and was developed as paramedic medicine against psoriasis. This review provides an overall summary of 558 new natural SQs discovered between 2010 and 2021, including seven groups and sixteen structure-type subgroups, which comprehensively recapitulates their chemical structures, spectral characteristics, source organisms, biological activities, synthesis, and biosynthesis, aiming to expand the application scope of this unique natural product resource.

Alkaloids, sesquiterpenoids and hybrids of terpenoid with p-hydroxycinnamic acid from Ganoderma sinensis and their biological evaluation

The fruiting bodies of Ganoderma sinensis are used as food raw materials of marketed healthcare products. To gain an insight into the chemical and biological profling of G. sinensis, twenty-five compounds including eleven undescribed ones (ganodermasines A‒K) and fourteen known ones were isolated. Among them, ganodermasines A‒D are undescribed diketopiperazine alkaloids, ganodermasines E and F are alkaloids containing a pyridine. The structures of undescribed compounds were identified by spectroscopic, computational, and crystallographic methods. The results of acetylcholinesterase (AchE) inhibitory activity show that ganodermasines I and J could inhibit AchE with IC₅₀ values of 26.05 and 20.40 μM, respectively. In addition, neurotrophic assay in PC-12 cells showed that (+)-ganodermasine E, (-)-ganodermasine E, and ganodermasine I could stimulate neurite outgrowth at 10 μM, while the other isolates are inactive. The present findings will lend a hand for further utilization of G. sinensis.

Biological activities of meroterpenoids isolated from different sources

Meroterpenoids are natural products synthesized by unicellular organisms such as bacteria and multicellular organisms such as fungi, plants, and animals, including those of marine origin. Structurally, these compounds exhibit a wide diversity depending upon the origin and the biosynthetic pathway they emerge from. This diversity in structural features imparts a wide spectrum of biological activity to meroterpenoids. Based on the biosynthetic pathway of origin, these compounds are either polyketide-terpenoids or non-polyketide terpenoids. The recent surge of interest in meroterpenoids has led to a systematic screening of these compounds for many biological actions. Different meroterpenoids have been recorded for a broad range of operations, such as anti-cholinesterase, COX-2 inhibitory, anti-leishmanial, anti-diabetic, anti-oxidative, anti-inflammatory, anti-neoplastic, anti-bacterial, antimalarial, anti-viral, anti-obesity, and insecticidal activity. Meroterpenoids also possess inhibitory activity against the expression of nitric oxide, TNF- α, and other inflammatory mediators. These compounds also show renal protective, cardioprotective, and neuroprotective activities. The present review includes literature from 1999 to date and discusses 590 biologically active meroterpenoids, of which 231 are from fungal sources, 212 are from various species of plants, and 147 are from marine sources such as algae and sponges.

The chemistry and biology of fungal meroterpenoids (2009-2019)

Fungal meroterpenoids are secondary metabolites from mixed terpene-biosynthetic origins. Their intriguing chemical structural diversification and complexity, potential bioactivities, and pharmacological significance make them attractive targets in natural product chemistry, organic synthesis, and biosynthesis. This review provides a systematic overview of the isolation, chemical structural features, biological activities, and fungal biodiversity of 1585 novel meroterpenoids from 79 genera terrestrial and marine-derived fungi including macrofungi, Basidiomycetes, in 441 research papers in 2009-2019. Based on the nonterpenoid starting moiety in their biosynthesis pathway, meroterpenoids were classified into four categories (polyketide-terpenoid, indole-, shikimate-, and miscellaneous-) with polyketide-terpenoids (mainly tetraketide-) and shikimate-terpenoids as the primary source. Basidiomycota produced 37.5% of meroterpenoids, mostly shikimate-terpenoids. The genera of Ganoderma, Penicillium, Aspergillus, and Stachybotrys are the four dominant producers. Moreover, about 56% of meroterpenoids display various pronounced bioactivities, including cytotoxicity, enzyme inhibition, antibacterial, anti-inflammatory, antiviral, antifungal activities. It's exciting that several meroterpenoids including antroquinonol and 4-acetyl antroquinonol B were developed into phase II clinically used drugs. We assume that the chemical diversity and therapeutic potential of these fungal meroterpenoids will provide biologists and medicinal chemists with a large promising sustainable treasure-trove for drug discovery.

Meroterpenoids produced by fungi: Occurrence, structural diversity, biological activities, and their molecular targets

Meroterpenoids are partially derived from the terpenoids, distributing widely in the plants, animals and fungi. The complex structures and diverse bioactivities of meroterpenoids have attracted more attention for chemists and pharmacologists. Since the first review summarized by Geris in 2009, there are absent of systematic reviews reported about meroterpenoids from the higher and lower fungi up to now. In the past decades, myriads of meroterpenoids were discovered, and it is necessary to summarize these meroterpenoids about their unique structures and promising bioactivities. In this review, we use a new classification method based on the non-terpene precursors, and also highlight the structural features, bioactivity of natural meroterpenoids from the higher and lower fungi covering the period of September 2008 to February 2020. A total of 709 compounds were discussed and cited the 182 references. Meanwhile, we also primarily summarize their occurrence, structural diversity, biological activities, and molecular targets.

Scientific rationale for the use of dietary supplements based on Ganoderma luсidum in the comprehensive prevention of dental caries in children

Relevance. Numerous studies on the etiology, diagnosis and treatment of decay of temporary teeth objectify the relevance of this problem. Currently used fluoride preparations are very effective, but nonetheless, there is an increase in caries from year to year. Therefore, as an addition to fluorine preparations, the use of dietary supplements based on Ganoderma Lucidum has been proposed.

Purpose. Conduct an open, randomized study of the dietary supplements based on the Ganoderma Lucidum in the comprehensive prevention of dental caries in children.

Materials and methods. To achieve this goal, 78 children aged 3 to 12 years were examined in terms of indicators: estimates of the prevalence of caries (%), the intensity of caries (CSD – carious, sealed, distant and CFS – carious, filled surfaces), the simplified OHI-S index (Green-Wermillion), CPITN, and oral cavity IG according to Kuzmina EM. (2000). All children, depending on the prevalence of caries, were divided into 2 groups: group 1 – the main (41 children, age 6.4 ± 4.8 years) – for complex prevention, fluoride preparations were used with dietary supplements based on Ganoderma Lucidum, group 2 – comparison group (37 children, age 7.3 ± 3.7 years) – fluorine preparations were used for complex prophylaxis.

Results. After 4 months of application of the dietary supplements based on Ganoderma Lucidum, an improvement in oral hygiene was recorded. So, in the main group, IG improved by 57% and amounted to 0.21 ± 0.02, in the comparison group – by 33% and amounted to 0.52 ± 0.03 (p≤0.05). In the comparison group, before the use of fluoride preparations, the% of sanitized was 63%, whereas after the use of fluorine this indicator was 72%. The CSD index before application was 3.32 ± 0.01 and after application was 2.56 ± 0.02. CPITN before use was 1.2 ± 0.04 whereas after use it was 0.76 ± 0.03. OHI-S before application was 40.03% and after application of fluorine it was 21.05%. The increase in caries before the use of fluorine was 0.76 ± 0.04 and after the use of fluorine was 0.33 ± 0.02.

Conclusions. The use of dietary supplements based on Ganoderma Lucidum in combination with fluorine preparations is more appropriate for a comprehensive prevention program than the usual use of fluorine preparations.